The Shadow Market: India’s Intensifying Crackdown on Banned Medicines and FDCs

Spread the Message

Read Time:5 Minute, 4 Second

NEW DELHI — In a significant move to safeguard public health, the Union Ministry of Chemicals and Fertilizers revealed this week a sharp escalation in the prohibition of unsafe pharmaceutical formulations. According to data presented in the Lok Sabha on February 6, 2026, the Central Government has banned over 170 drugs for human use since 2023, signaling a rigorous shift in regulatory oversight aimed at eliminating “irrational” drug combinations from the Indian market.

While the data highlights a proactive stance by the Central Drugs Standard Control Organisation (CDSCO), it also exposes a complex legal and regulatory tug-of-war. Despite federal bans, many of these medications remain on pharmacy shelves due to interim court protections, sparking concerns among healthcare advocates about patient safety and the clarity of the country’s drug distribution network.

The Surge in Prohibitions: A Three-Year Timeline

The statistics provided by Union Minister Shri Jagat Prakash Nadda illustrate a dramatic spike in regulatory activity. After two years of zero bans in 2021 and 2022, the government moved aggressively:

2023: 14 drugs for human use and 2 for animal use were banned.
2024: A record 157 drugs for human use and 1 for animal use were prohibited.
2025: Regulatory focus shifted toward veterinary safety, banning 36 animal drugs alongside 1 human formulation.

Most of these prohibitions target Fixed-Dose Combinations (FDCs). An FDC involves two or more active pharmaceutical ingredients (APIs) combined into a single pill or injection. While some FDCs are medically sound—such as those used to treat HIV or tuberculosis—many “unapproved” FDCs are created by manufacturers to bypass price controls or offer “cocktail” treatments for common ailments like colds and pain without scientific justification.

“Irrational FDCs are a major public health concern,” says Dr. Arati Sen, a clinical pharmacologist not involved in the government report. “They often expose patients to unnecessary ingredients, increasing the risk of side effects and, more critically, contributing to the global crisis of antimicrobial resistance.”

The Legal “Limbo”: Why Banned Drugs Persist

Perhaps the most troubling revelation in the Ministry’s report is the role of the judiciary in slowing the removal of these drugs. Several pharmaceutical manufacturers have filed writ petitions in High Courts across India, challenging the bans.

In many instances, courts have granted interim protection, allowing drugs already in the distribution pipeline to be sold until a final verdict is reached. This creates a “gray market” where a medicine may be legally banned by the Ministry of Health but remains legally available for purchase at a local chemist.

Under the Drugs & Cosmetics Act of 1940, the manufacture and sale of banned drugs is a punishable offense. However, the enforcement of these laws falls to State Licensing Authorities (SLAs). When the CDSCO receives a complaint regarding the sale of a prohibited substance, it must defer to State Drugs Controllers to take action, a process that critics argue can be slowed by bureaucratic hurdles and varying levels of state-level oversight.

Brand Name Deception and Composition Changes

The government is also tightening the noose on “brand name confusion.” In 2019, the Drugs and Cosmetics Rules were amended to require manufacturers to submit Form 51. This is a legal undertaking that the proposed brand name is unique and will not lead to “confusion or deception” in the market.

“We often see cases where a brand name remains the same, but the manufacturer changes the active ingredients without proper approval,” explains Rajesh Mehta, a veteran pharmaceutical policy analyst. “A patient might buy ‘Brand X’ thinking it contains the same medicine they took last year, but the formulation has changed. This is a recipe for medical errors.”

The Ministry confirmed that any change in the composition of active ingredients requires “New Drug” permission from the CDSCO. Review processes now fall under the more stringent New Drugs and Clinical Trial Rules, 2019, which demand more robust evidence of safety and efficacy.

What This Means for Consumers

For the average Indian household, the regulatory jargon translates to a simple warning: Not every pill in the cabinet is vetted for safety.

How to Protect Yourself:

Check for “Rationality”: Be wary of “cocktail” medications that claim to treat five symptoms at once (e.g., a single pill for cough, cold, headache, and body pain).
Verify Brand Changes: If the packaging or color of your regular medication changes, ask your pharmacist or doctor if the ingredients have been altered.
Consult Professionals: Avoid over-the-counter (OTC) purchases of antibiotics or complex pain relievers without a valid prescription from a registered medical practitioner.
Report Side Effects: If you experience unusual reactions to a common drug, report it to the Pharmacovigilance Programme of India (PvPI).

The Path Forward: Public Health vs. Industrial Interests

While the pharmaceutical industry argues that FDCs offer convenience and better patient compliance, the medical community remains cautious. The sheer volume of bans in 2024 suggests that the government is finally addressing a long-standing backlog of unscientific formulations.

However, the “interim protection” granted by courts remains a loophole. Public health experts are calling for a more streamlined legal process to ensure that once a drug is deemed unsafe or irrational by a technical committee, its removal from the market is immediate and absolute.

“The safety of 1.4 billion people cannot be held hostage by litigation,” says Dr. Sen. “We need a unified digital database where consumers can instantly check if a batch number belongs to a banned list.”

As the CDSCO and State Controllers work to synchronize their enforcement, the message from New Delhi is clear: The era of “anything goes” in pharmaceutical combinations is coming to an end.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.